Related Experiment Videos
The arotinoids: early clinical experience and discussion of future development
A Arnold1, B Kowaleski, R Tozer
1Department of Medical Oncology, Hamilton Regional Cancer Centre, Ontario, Canada.
Leukemia
|January 1, 1994
Summary
New retinoids, like arotinoid Ro 40-8757, show distinct anti-cancer properties and potential for bone marrow protection. Further research into retinoid combinations is recommended for enhanced cancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Retinoids are compounds that modify malignant cell properties.
- Established retinoids include ATRA and 13-CRA.
- Newer synthetic retinoids like fenretinide, Ro 40-8757, and 9-cis retinoic acid are in clinical trials.
Purpose of the Study:
- To highlight the unique properties of the arotinoid Ro 40-8757.
- To explore its distinct binding proteins and gene regulation compared to classical retinoids.
- To assess its potential against various malignancies and its side-effect profile.
Main Methods:
- Review of existing research on retinoids, focusing on Ro 40-8757.
- Comparison of Ro 40-8757's molecular interactions and gene regulation with ATRA and 13-CRA.
- Evaluation of its efficacy spectrum and safety profile.
Main Results:
- Ro 40-8757 exhibits distinct properties from classical retinoids, including different binding proteins and gene regulation.
- It shows activity against a different spectrum of malignancies with a favorable side-effect profile.
- Potential role in protecting bone marrow function post-cytotoxic drug use.
Conclusions:
- Ro 40-8757's development was halted due to resource limitations.
- Future retinoid development should explore preclinical combination findings.
- Retinoids are best viewed as modulators enhancing other anticancer agents, not standalone treatments for solid tumors.